Have a feature idea you'd love to see implemented?
Let us know!
CDXC ChromaDex Corp
Price (delayed)
$7.63
Market cap
$582.8M
P/E Ratio
763
Dividend/share
N/A
EPS
$0.01
Enterprise value
$553.3M
ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create
Highlights
The company's EPS has surged by 150% QoQ and by 111% YoY
The company's net income has surged by 123% YoY
Key stats
What are the main financial stats of CDXC
Market
Valuations
Earnings
Shares outstanding
76.38M
Market cap
$582.8M
Enterprise value
$553.3M
Price to earnings (P/E)
763
Price to book (P/B)
16.86
Price to sales (P/S)
6.32
EV/EBIT
296.84
EV/EBITDA
164.53
EV/Sales
6.04
Revenue
$91.67M
EBIT
$1.86M
EBITDA
$3.36M
Free cash flow
$4.08M
Per share
Balance sheet
Liquidity
EPS
$0.01
Free cash flow per share
$0.05
Book value per share
$0.45
Revenue per share
$1.21
TBVPS
$0.74
Total assets
$56.52M
Total liabilities
$22.15M
Debt
$2.9M
Equity
$34.37M
Working capital
$34.44M
Debt to equity
0.08
Current ratio
2.95
Quick ratio
2.23
Net debt/EBITDA
-8.77
Margins
Efficiency
Dividend
EBITDA margin
3.7%
Gross margin
61.4%
Net margin
1.6%
Operating margin
0.5%
Return on assets
2.7%
Return on equity
4.8%
Return on invested capital
18.9%
Return on capital employed
4.8%
Return on sales
2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CDXC stock price
How has the ChromaDex stock price performed over time
Intraday
1.73%
1 week
5.97%
1 month
120.52%
1 year
429.86%
YTD
433.57%
QTD
109.04%
Financial performance
How have ChromaDex's revenue and profit performed over time
Revenue
$91.67M
Gross profit
$56.33M
Operating income
$447,000
Net income
$1.49M
Gross margin
61.4%
Net margin
1.6%
ChromaDex's net margin has soared by 200% from the previous quarter and by 121% YoY
The company's net income has surged by 123% YoY
CDXC's operating margin has surged by 119% since the previous quarter and by 106% year-on-year
ChromaDex's operating income has surged by 119% QoQ and by 107% YoY
Growth
What is ChromaDex's growth rate over time
Valuation
What is ChromaDex stock price valuation
P/E
763
P/B
16.86
P/S
6.32
EV/EBIT
296.84
EV/EBITDA
164.53
EV/Sales
6.04
The company's EPS has surged by 150% QoQ and by 111% YoY
CDXC's price to book (P/B) is 144% higher than its last 4 quarters average of 6.9 and 89% higher than its 5-year quarterly average of 8.9
The equity rose by 26% year-on-year and by 12% since the previous quarter
CDXC's price to sales (P/S) is 153% higher than its last 4 quarters average of 2.5 and 66% higher than its 5-year quarterly average of 3.8
The revenue has grown by 10% YoY and by 7% from the previous quarter
Efficiency
How efficient is ChromaDex business performance
CDXC's return on invested capital has surged by 141% year-on-year
The company's return on sales has surged by 126% YoY
ChromaDex's return on assets has surged by 122% YoY
The company's return on equity has surged by 121% YoY
Dividends
What is CDXC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CDXC.
Financial health
How did ChromaDex financials performed over time
The total assets is 155% more than the total liabilities
CDXC's quick ratio is up by 34% year-on-year and by 12% since the previous quarter
The current ratio has increased by 21% year-on-year and by 7% since the previous quarter
ChromaDex's debt is 92% less than its equity
CDXC's debt to equity is down by 43% year-on-year and by 20% since the previous quarter
The equity rose by 26% year-on-year and by 12% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.